FY2025 · ended Dec 31, 2025 · Revenue $272.30M, +36.4% YoY · Filed Mar 2, 2026
Harrow, Inc. (HROW) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $272.3 million and a net loss of $5.1 million. Free cash flow was $43.0 million. As of Jun 30, 2026 it held $83.9 million in cash and investments and $8.4 million in total debt.
Revenue (TTM)
$275.59M
+21.1% vs year-ago TTM
Net income (TTM)
$-37.23M
-264.0% vs year-ago TTM
Operating cash flow (TTM)
$6.25M
+54.9% vs year-ago TTM
Free cash flow (TTM)
$5.02M
+97.3% vs year-ago TTM
EPS (TTM)
$-1.00
-252.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
37.23M
+4.4% vs prior year
Net cash
$75.52M
as of Jun 30, 2026
Operating margin
-1.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HROW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Nashville, TN
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1360214
- Former names
- HARROW HEALTH, INC. (until Sep 20, 2023); Imprimis Pharmaceuticals, Inc. (until Dec 17, 2018); TRANSDEL PHARMACEUTICALS INC (until Feb 27, 2012); Bywater Resources, Inc (until Sep 12, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $272.3M | $199.6M | $130.2M | $88.6M | $72.5M |
| Operating income | $30.5M | $8.8M | $431,000 | $1.9M | $1.6M |
| Net income | -$5.1M | -$17.5M | -$24.4M | -$14.1M | -$18.0M |
| Diluted EPS | -$0.14 | -$0.49 | -$0.75 | — | — |
| Operating cash flow | $43.9M | -$22.2M | $3.8M | $1.7M | $5.1M |
| Free cash flow | $43.0M | -$23.8M | $2.4M | -$892,000 | $3.3M |
| Total assets | $399.5M | $389.0M | $312.2M | $157.4M | $98.3M |
| Total liabilities | $347.4M | $319.7M | $241.8M | $130.1M | $87.4M |
| Stockholders' equity | $52.4M | $69.7M | $70.8M | $27.6M | $11.3M |
| Cash and investments | $72.9M | $47.2M | $82.8M | $5.6M | $42.2M |
| Total debt | $258.8M | $272.0M | $254.0M | $159.8M | $109.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Regulation FD disclosure
|
Oct 5, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 4, 2026 | Sep 4, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Aug 6, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 22, 2026 | Jun 18, 2026 |
All 868 Harrow, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.